This page uses content from Wikipedia and is licensed under CC BY-SA.


Clinical data
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding36%
Elimination half-life17–20 hours
CAS Number
PubChem CID
Chemical and physical data
Molar mass231.257 g/mol g·mol−1
3D model (JSmol)

Dexfenfluramine, marketed as dexfenfluramine hydrochloride under the name Redux, is a serotonergic anorectic drug: it reduces appetite by increasing the amount of extracellular serotonin in the brain.[1] It is the d-enantiomer of fenfluramine and is structurally similar to amphetamine, but lacks any psychologically stimulating effects.

Dexfenfluramine was, for some years in the mid-1990s, approved by the United States Food and Drug Administration for the purposes of weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug,[1] the FDA withdrew the approval in 1997.[2] After it was removed in the US, dexfenfluramine was also pulled out in other global markets. It was later superseded by sibutramine, which, although initially considered a safer alternative to both dexfenfluramine and fenfluramine[citation needed], was likewise removed from the US market in 2010.[3]

The drug was developed by Interneuron Pharmaceuticals, a company co-founded by Richard Wurtman, aimed at marketing discoveries by Massachusetts Institute of Technology scientists.[4] Interneuron licensed the patent to Wyeth-Ayerst Laboratories.[5] Although at the time of its release, some optimism prevailed that it might herald a new approach[citation needed], there remained some reservations amongst neurologists, twenty-two of whom petitioned the FDA to delay approval[citation needed]. Their concern was based on the work of George A. Ricaurte, whose techniques and conclusions were later questioned.[6]

See also


  1. ^ a b Stuart Ira Fox. Human Physiology. Twelfth Edition. McGraw Hill. 2011. p.665.
  2. ^ FDA September 15, 1997. FDA Announces Withdrawal Fenfluramine and Dexfenfluramine (Fen-Phen)
  3. ^ "Abbott Pulls Diet Drug Meridia Off US Shelves". Wall Street Journal. 8 October 2010. Archived from the original on 23 October 2010.
  4. ^ Lemonick, Michael D; Dowell, William; Nash, J. Madeleine; Ramirez, Ainissa; Reid, Brian; Ressner, Jeffrey (23 September 1996), "The New Miracle Drug?", Time, archived from the original on 6 November 2010, retrieved 3 October 2010
  5. ^ Lemonick, Michael D; Nash, J. Madeleine; Park, Alice; Thompson, Dick (29 September 1997), "The Mood Molecule", Time, archived from the original on 3 October 2008, retrieved 4 October 2010
  6. ^ "DEA Accedes to Ecstasy Test". Wired. 2 March 2004.

External links